Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Motexafin Gadolinium Injection
motexafin gadolinium · 10 trials · 26 indications
| Name | Type | Description |
|---|---|---|
| Motexafin Gadolinium | DRUG | - |
| Motexafin Gadolinium Injection | DRUG | - |
Inclusion Criteria: * Adults (≥18 years old) with radiologically proven parenchymal brain metastases from histologically confirmed non-small cell lung cancer; * KPS score of ≥70; * Each patient must sign a study-specific Informed Consent form Exclusion Criteria: * Liver metastases; * Extracranial...
Motexafin gadolinium is an investigational small molecule being studied in oncology for several cancer types, including chronic lymphocytic leukemia, renal cell carcinoma, non-small-cell lung cancer, breast cancer, glioma, and brain neoplasms. It has been evaluated in Phase 1 and Phase 2 clinical trials, but is not approved for any indication.
Motexafin gadolinium targets RRM1, RRM2, RRM2B, and TXNRD1. It acts as an inhibitor of these proteins, which are involved in ribonucleotide reduction and redox regulation. By inhibiting these targets, the drug is thought to disrupt DNA synthesis and cellular antioxidant defenses in cancer cells.
Motexafin gadolinium is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. The company is responsible for the clinical development of the drug, which is currently in Phase 2 testing.
Motexafin gadolinium is in Phase 2 clinical development. It has completed two trials, including a Phase 1 study in chronic lymphocytic leukemia and small lymphocytic lymphoma, and a Phase 2 study in renal cell carcinoma. No active trials are currently recruiting.
Motexafin gadolinium has been studied in completed trials including NCT00290004 (Phase 1 in chronic lymphocytic leukemia or small lymphocytic lymphoma), NCT00134186 (Phase 2 in renal cell cancer), NCT00129844 (Phase 2 in non-small-cell lung cancer), and NCT00120939 (Phase 1 with docetaxel in advanced cancers). All trials are completed.
Yes, Motexafin Gadolinium Injection is another name for motexafin gadolinium. Both terms refer to the same investigational small molecule developed by AbbVie Inc. for oncology indications.